Insmed (Insmed) Total Current Assets

: $929.1 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Insmed's total current assets for the quarter that ended in Dec. 2023 was $929.1 Mil.

Insmed Total Current Assets Historical Data

The historical data trend for Insmed's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

555.19

622.89

837.04

1,273.38

929.06

Insmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															1,273.38	1,129.06	1,052.42	926.58	929.06

Insmed Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Insmed's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	780.447	+	41.189	+	83.248	+	24.179
	=	929.1

Insmed's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	780.447	+	41.189	+	83.248	+	24.179
	=	929.1

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Insmed (NAS:INSM) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Insmed's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	780.447	-	1661.76	+	0.75 * 41.189	+	0.5 * 83.248
=	-808.8

Insmed Total Current Assets Related Terms

Thank you for viewing the detailed overview of Insmed's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed (Insmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

INSM:Mexico IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Executives

Flammer Martina M.d.	officer: Chief Medical Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett	officer: Chief Commercial Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise	officer: Chief Commercial Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith	officer: General Counsel, Senior VP	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis	officer: President & CEO	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole	officer: Chief People Strategy Officer	INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano	officer: Chief Compliance Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari	officer: General Counsel & Secretary	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807